Loading clinical trials...
Loading clinical trials...
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Conditions
Interventions
Denosumab
Placebo
Locations
172
United States
Research Site
Anaheim, California, United States
Research Site
Laguna Hills, California, United States
Research Site
Murrieta, California, United States
Research Site
San Diego, California, United States
Research Site
San Diego, California, United States
Research Site
San Diego, California, United States
Start Date
November 30, 2009
Primary Completion Date
May 12, 2016
Completion Date
May 12, 2016
Last Updated
May 30, 2017
NCT05468034
NCT04541381
NCT06204094
NCT07446322
NCT06713993
NCT07489378
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions